Jason T. Hindman

机构：Gilead Sciences (Spain), Gilead Sciences (United States), Gilead Sciences (Australia) · ORCID：0000-0003-1513-3423

发表论文 43 篇 · 总被引 668 次 · h-index 11

代表论文

• Pharmacokinetics of long-acting lenacapavir in participants with hepatic or renal impairment (2024 · Antimicrobial Agents and Chemotherapy · 被引 20)
• Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy (2024 · AIDS · 被引 18)
• Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV: a phase 2/3, open-label, single-arm study (2024 · The Lancet HIV · 被引 13)
• High efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Black adults in the United States, including those with pre‐existing HIV resistance and suboptimal adherence (2024 · Journal of Medical Virology · 被引 12)
• Efficacy of bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir-based three-drug regimens in people with HIV with varying adherence to antiretroviral therapy (2024 · Journal of Antimicrobial Chemotherapy · 被引 10)
• Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV (2025 · AIDS Research and Therapy · 被引 6)